Treace Medical Concepts (TMCI)

• Market cap: $584M
• 1 day: -3.00%
• 5 days: -8.23%
• 1 month: 1.08%
• 3 months: 18.01%
• 6 months: 45.27%
• Year to date: 19.06%
• 1 year: -37.20%
• 5 years: -63.30%
• 10 years: -63.30%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.

Employees: 227

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

736% more call options, than puts

Call options by funds: $1.21M | Put options by funds: $145K

18% more capital invested

Capital invested by funds: $235M [Q3] → $277M (+$42M) [Q4]

9% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 22

1% less funds holding

Funds holding: 132 [Q3] → 131 (-1) [Q4]

9% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 45

5.35% less ownership

Funds ownership: 65.14% [Q3] → 59.79% (-5.35%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 15% downside
• Avg. target: $10.30 10% upside
• High target: $14.50 55% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

Lake Street Ben Haynor 38% 1-year accuracy 3 / 8 met price target	55% upside $14.50	Buy Initiated	31 Dec 2024
Truist Securities Richard Newitter 77% 1-year accuracy 33 / 43 met price target	10% downside $8.40	Hold Maintained	18 Dec 2024
JP Morgan Lilia-Celine Lozada 50% 1-year accuracy 1 / 2 met price target	15% downside $8	Neutral Assumed	17 Dec 2024